Pulmonary Arterial Hypertension: One More Catheter Before the Next Drug
A single patient, six months into first-line combination therapy for idiopathic pulmonary arterial hypertension, improving by some measures and not at all by others. The disagreement is whether that mixed result is reason enough to repeat an invasive test before choosing the next drug, or reason enough to choose it without one.
R.D., a 52-year-old man who has coached his high school's cross-country team for fourteen years, is used to running alongside his athletes through August double-practice sessions and pacing a full invitational meet from start line to finish every Saturday of the fall. Last year, for the first time, the walk from the parking lot to the starting line left him stopping twice to catch his breath, and within a few months he couldn't finish pacing a meet without sitting down partway through. Previously healthy apart from well-controlled hypertension on a low-dose thiazide, it took nearly eight months of climbing breathlessness in total before a cardiology referral led to a right heart catheterization six months ago: mean pulmonary artery pressure 46 mmHg, pulmonary vascular resistance 6.8 Wood units, wedge pressure normal at 10 mmHg, cardiac index reduced at 2.3 L/min/m². No connective tissue disease, no HIV, no portal hypertension, no toxin or drug exposure — idiopathic pulmonary arterial hypertension, World Health Organization functional class III at diagnosis. He started ambrisentan and tadalafil together that same day, the initial oral combination now standard for a treatment-naive patient at his risk level.
Six months later, the follow-up numbers don't all point the same direction. His functional class has genuinely improved, to class II — he coached the entire spring track season without sitting down. His six-minute walk distance rose from 320 to 390 meters, real progress but still short of the distance associated with a low-risk classification. His NT-proBNP fell from 850 to 410 pg/mL, cut by more than half but still above the threshold that would call it reassuring on its own. And his echocardiogram looks almost unchanged from diagnosis — the right ventricle still moderately enlarged, tricuspid annular excursion still reduced, with no clear gain in right ventricular function to match how much better he says he feels. Taken together, the follow-up risk model used to guide therapy after first-line combination classifies him as intermediate risk, the category current guidelines say should prompt escalating beyond his two drugs. What it can't settle on its own is whether the pulmonary vascular resistance that justified starting therapy six months ago has actually come down, or whether a right ventricle that still looks like it did at his worst reflects a problem his improved walk distance and functional class have not resolved.
Six months in, reviewing the follow-up numbers
I want a repeat catheterization before we add anything. Six months ago, the number that put him at real risk was a pulmonary vascular resistance of 6.8 Wood units — not his walk distance, not how he says he feels. Everything reassuring in this chart is either subjective or a step removed from the disease itself: his functional class, his six-minute walk, even his NT-proBNP are downstream consequences of right ventricular performance, and his echocardiogram — the one test here that looks directly at the right ventricle — hasn't moved at all. When the noninvasive story and the imaging disagree this cleanly, that is exactly the situation invasive hemodynamics exists to settle, not skip.
If everything here pointed the same direction — a walk distance over 440 meters, an NT-proBNP under 300, an echocardiogram actually showing recovery — I wouldn't be arguing for another catheter. It's the disagreement between his own tests that changes my answer here, not a blanket preference for invasive data over noninvasive.
The follow-up model he's being staged against was built from exactly this kind of patient — better by some measures, not by others — and it already tells us what to do. He's intermediate risk on the three variables it actually uses, and the guideline answer to intermediate risk after first-line ambrisentan and tadalafil is to add a third agent, not to reopen the hemodynamic question first. Selexipag is the added agent with the stronger trial evidence behind it at this stage. Waiting on a catheterization to confirm what the risk category already indicates costs him real weeks on two drugs when the data already support three.
The echocardiogram not moving is real, but TAPSE is load-dependent and lags clinical improvement in plenty of patients who go on to do well — it isn't the tie-breaker it's being treated as here.
I don't think this has to be a choice between the two. Nothing about starting selexipag today requires knowing his exact current pulmonary vascular resistance — the intermediate-risk classification already clears that bar on its own. What I'd change is only the sequencing: start the third agent now, and put the catheterization on the calendar as his next planned reassessment, at the point where we'd want real hemodynamic numbers anyway to judge whether it worked — not as a gate in front of a decision the noninvasive data has already made.
Agreed: start selexipag today at the standard low starting dose with the planned uptitration schedule, continuing ambrisentan and tadalafil unchanged. A right heart catheterization is scheduled for three months from now, timed to the point where the group will want real hemodynamic numbers to judge whether the third agent worked — not held in front of today's decision.
Not agreed: whether that catheterization should have come before today's decision instead of after it.
The intermediate-risk classification and today's escalation will have been vindicated without ever needing to delay for confirmation — the more efficient path, and evidence the noninvasive approach worked as intended.
The persistently reduced TAPSE will have been the earlier, correct warning sign — and the interval spent on selexipag without knowing his true pulmonary vascular resistance will be the interval a catheterization obtained today would have skipped.
The Cardiologist and Clinical Pharmacologist ended the visit agreeing on the prescription; the Pulmonologist held that a catheterization obtained today, not in three months, would have been the more defensible standard for a patient whose imaging and functional trend genuinely disagree — a position the group didn't adopt, but didn't resolve either.